Stent Choice Matters
Small differences between stents can be the determining factor on whether clinical outcomes are optimal over the short and long-term.1,2
There’s a Whole World of Evidence in Support of the XIENCE™ Stent
Clinicians have long had confidence in XIENCE™ Stent, which industry experts consider to be the gold standard. XIENCE™ Stent is the world's leading DES, with over 20 million implants, consistently delivering outstanding short- and long-term outcomes.1,3
The XIENCE™ Stent difference results not just from a unique stent design but from a unique fluoropolymer coating. This coating is a key differentiator from other DES, resulting in thromboresistance, and minimal inflammatory response with XIENCE™ Stents.2,5
Peak Performance with XIENCE™ Stent
The XIENCE™ Stent is effective in a wide range of patients—from simple lesions to complex lesions, and from lower risk individuals to higher risk patients like those with diabetes.6
Here are a few of the features that contribute to XIENCE™ Stent quality and performance:7
- Excellent deliverability
- Ultra-low stent crossing profile (0.0390")
- XIENCE Skypoint™ Stent's unique design to post dilate to 5.75 mm
- Flexible and conformable MULTI-LINK design
- Minimal stent shortening when deployed
References
- Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
- Jinnouchi H, et al. J Am Coll Cardiol. 2019;74:Suppl B – TCT-291.
- Data on file at Abbott. The 20 million implants is based on DES data through Q2, 2022.
- Kufner S, et al. Circulation. 2019:139(3):325-333.
- Otsuka F, et al. JACC Cardiovasc Interv. 2015;8:1248-1260.
- Kaul U, et al. TUXEDO-India trial. EuroIntervention. 2017;13:1194-1201.
- Data on file at Abbott. Bench test results may not necessarily be indicative of clinical performance. Testing performed on XIENCE Skypoint™ Stent (3.0 x 18 mm, n=10), SYNERGY‡ (3.0 x 20 mm, n=10), Resolute Onyx‡ (3.0 x 18 mm, n=10). Crossing performance - XIENCE Skypoint™ Stent (3.0 x 18 mm, n=5) and SYNERGY‡ (3.0 x 20 mm, n=5).
MAT-2104268 v4.0